Renal denervation is a minimally invasive, catheter-based endovascular treatment that treats resistant hypertension by radiofrequency ablation or ultrasound ablation. Applying radiofrequency bursts or ultrasound to the renal arteries will ablate the nerves that are present in their walls. For the treatment of resistant high blood pressure that is resistant to medication, the device employs radiofrequency ablation, pharmacologic ablation, or ultrasound ablation.
The market for renal denervation in 2021 was worth USD 219.49 million
, and by 2030 it will be worth USD 4743.13 million, growing at a 40.7% CAGR during the forecast period.
The rising prevalence of severe health conditions such as high blood pressure or hypertension will boost the global renal denervation market. Furthermore, increasing investments in renal sympathetic denervation innovations and research and development activities will generate a lucrative opportunity for growth in the global renal denervation market over the forecast period.
Rapid technological advancements in therapy methods and the steadily rising number of patients with treatment-resistant hypertension worldwide are key factors anticipated to propel the growth of the global renal denervation market. Other factors stimulating market growth include the rising geriatric population in developing nations and the rising demand for minimally invasive therapy. Additionally, rising healthcare spending by developing country governments, a shifting regulatory environment, and players’ strategies for monitoring untapped markets in emerging economies will contribute to the global market’s expansion over the coming years.
Major elements limiting market expansion are the availability of other advanced technologies, stringent regulatory body approvals, poor reimbursement, and a shortage of qualified healthcare workers.
Due to the global rise in high blood pressure, the medical and healthcare industries are interested in the renal denervation industry. Additionally, the expansion of medical equipment in emerging nations and the acquisition of substitute and superior technologies for equipment-saving systems, such as micro-perfusion, are anticipated to propel market development.
Additionally, the market will grow in the coming years due to the increased use of products like Medtronic Symplicity Spyral renal denervation, EnligHTN, Vessix V2, Paradise, Iberis, and RENLANE.
The radiofrequency ablation segment led the entire market with a revenue share of nearly 78.15%. Radiofrequency ablation has numerous benefits, including safety, time efficiency, and so on. Furthermore, Radiofrequency Ablation is a one-time operation that is effective for at least two years in the treatment of hypertension. All of these reasons are effectively driving the segment’s growth. According to a study, radiofrequency ablation is 70% to 80% effective in individuals with critical nerve blocks. Furthermore, if a patient’s degree of relief is minimal after radiofrequency ablation treatments, the procedure can be repeat in two or three weeks.
Europe was the biggest regional market in 2020, with a revenue share of nearly 65.58%. This is mainly due to increased government funding for R&D activities and the region’s continuously increasing cases of hypertension. According to one survey, more than 40% of Europeans over the age of 25 have hypertension. With 10% having medication-resistant hypertension. In 2020, Germany had the greatest prevalence of hypertension (around 55%), followed by Finland (nearly 49%), Spain (approximately 47%), England (approximately 42%), Sweden (approximately 38%), and Italy (approximately 38%).
According to the Places for Infectious prevention and Avoidance (CDC), in 2013, in excess of 360,000 individuals in America kicked the bucket because of hypertension. The event of hypertension has expanded from 17,307 for every 100,000 out of 1990 to 20,525 for each 100,000 out of 2015. Notwithstanding, renal denervation treatment has shown a positive outcome in lessening hypertension. Accordingly, the benefits presented by these treatments, for example, extremely durable impact, diminished treatment time, and higher wellbeing, are supporting the market development. Moreover, the headway of renal denervation gadgets is probably going to drive the market.
- Cardiotonic Ltd
- Boston Scientific Corporation
- Abbott Laboratories
- Ablative Solutions, Inc
- Johnson & Johnson
- Medtronic plc
- Renal Dynamics Limited
- Mercator MedSystems, Inc
- ReCor Medical, Inc
- Terumo Corporation
The market for renal denervation in 2021 was worth USD 219.49 million. And by 2030 it will be worth USD 4743.13 million, growing at a 40.7% CAGR during the forecast period. The market growth is stimulate by the rapid growth of the renal denervation system. The rise in cases of hypertension caused by drinking alcohol and eating unhealthy foods. The expanding use of endovascular catheters and radiofrequency ablation, and the ongoing increase in heart failure cases.
Carbon Black Market Report – The global carbon black market will witness a robust CAGR of 5.5%. Valued at $13.45 billion
in 2021, expected to appreciate and reach $21.85 billion by 2030, confirms Strategic Market Research.